相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Melphalan pharmacokinetics and transplant related toxicity during autologous stem cell transplantation
Ugur Sahin et al.
BONE MARROW TRANSPLANTATION (2021)
Long-term outcomes of busulfan plus melphalan-based versus melphalan 200 mg/m(2) conditioning regimens for autologous hematopoietic stem cell transplantation in patients with multiple myeloma: a systematic review and meta-analysis
Fei Gao et al.
CANCER CELL INTERNATIONAL (2021)
Hematopoietic stem cell transplantation activity in China 2019: a report from the Chinese Blood and Marrow Transplantation Registry Group
Lan-Ping Xu et al.
BONE MARROW TRANSPLANTATION (2021)
Prevalence and Incidence of Multiple Myeloma in Urban Area in China: A National Population-Based Analysis
Shengfeng Wang et al.
FRONTIERS IN ONCOLOGY (2020)
Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trial
Qaiser Bashir et al.
LANCET HAEMATOLOGY (2019)
Current status of autologous stem cell transplantation for multiple myeloma
Rama Al Hamed et al.
BLOOD CANCER JOURNAL (2019)
Busulfan plus melphalan versus high-dose melphalan as conditioning regimens in autologous stem cell transplantation for newly diagnosed multiple myeloma
Ja Min Byun et al.
BLOOD RESEARCH (2018)
Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis
Imke H. Bartelink et al.
Lancet Haematology (2016)
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
S. Vincent Rajkumar et al.
LANCET ONCOLOGY (2014)
Prospective cohort study comparing intravenous busulfan to total body irradiation in hematopoietic cell transplantation
Christopher Bredeson et al.
BLOOD (2013)
Efficacy and Safety of Busulfan-Based Conditioning Regimens for Multiple Myeloma
Donna Reece et al.
ONCOLOGIST (2013)
Busulfan 12 mg/kg plus melphalan 140 mg/m2 versus melphalan 200 mg/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 study
Juan Jose Lahuerta et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
Busulfan in Hematopoietic Stem Cell Transplantation
Stefan O. Ciurea et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2009)
Autologous SCT with a dose-reduced BU and CY regimen in older patients with non-Hodgkin's lymphoma
R. Z. Yusuf et al.
BONE MARROW TRANSPLANTATION (2009)
BU and CY as conditioning regimen for autologous transplant in patients with multiple myeloma
G. Talamo et al.
BONE MARROW TRANSPLANTATION (2009)
Management of multiple myeloma: The changing landscape
Donna E. Reece
BLOOD REVIEWS (2007)
High-dose melphalan versus busulfan, cyclophosphamide, and etoposide as preparative regimens for autologous stem cell transplantation in patients with multiple myeloma
Don M. Benson et al.
LEUKEMIA RESEARCH (2007)
Modified conditioning regimen busulfan-cyclophosphamide followed by allogeneic stem cell transplantation in patients with multiple myeloma
Zhang Xiao-hui et al.
CHINESE MEDICAL JOURNAL (2007)
International uniform response criteria for multiple myeloma
B. G. M. Durie et al.
LEUKEMIA (2006)
Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States
O Landgren et al.
BLOOD (2006)
International staging system for multiple myeloma
PR Greipp et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Favourable results with a single autologous stem cell transplant following conditioning with busulphan and cyclophosphamide in patients with multiple myeloma
AA Toor et al.
BRITISH JOURNAL OF HAEMATOLOGY (2004)
Comparison of high-dose melphalan with a more intensive regimen of thiotepa, busulfan, and cyclophosphamide for patients with multiple myeloma
A Anagnostopoulos et al.
CANCER (2004)
Comparison of 200 mg/m2 melphalan and 8 Gy total body irradiation plus 140 mg/m2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma:: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial
P Moreau et al.
BLOOD (2002)
分享论文
